[144] Axsome Therapeutics, Inc SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Axsome Therapeutics, Inc. (AXSM) shows a proposed sale of 20,000 common shares through Charles Schwab & Co., Inc. on 08/26/2025 with an aggregate market value of $2,400,658. The filing lists total outstanding shares of 49,901,487. The shares were originally acquired by exercise and hold on 05/27/2016 (1,298 shares) and 03/15/2017 (18,702 shares) from Axsome Therapeutics, Inc., both paid in cash. The filing also discloses a prior sale on 08/22/2025 of 16,694 shares for $2,004,598 by the seller identified as Roger Jeffs. The notice includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Insider intends to sell 20,000 AXSM shares worth ~$2.4M; prior sale of 16,694 shares occurred days earlier.

The filing documents an insider sale process under Rule 144 rather than a company liquidity event. The proposed 20,000-share sale equals roughly 0.04% of the stated outstanding shares (49,901,487), which is immaterial to capitalization. Acquisition dates from 2016 and 2017 indicate these are long-held, exercised securities. The recent prior sale (08/22/2025) of 16,694 shares for $2,004,598 shows active disposition over the same week. For investors, this is a routine disclosure of insider selling activity without explicit indication of company operational changes.

Corporate Governance Specialist

TL;DR: Rule 144 filing documents compliant insider stock sales with written representation about lack of undisclosed material information.

The form includes the standard attestation that the seller does not possess undisclosed material adverse information and notes no 10b5-1 plan date is provided. The seller’s use of a broker and prior nearby sale suggests staged disposition rather than a block trade. From a governance perspective, the filing meets disclosure norms; absent other context, it signals routine insider liquidity rather than governance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	20000	2400658.00	49901487	08/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/27/2016	Exercise and Hold	Axsome Therapeutics, Inc.			1298	05/27/2016	Cash
Common	03/15/2017	Exercise and Hold	Axsome Therapeutics, Inc.			18702	03/15/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ROGER JEFFS ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	08/22/2025	16694	2004598.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for AXSM report?

The filing reports a proposed sale of 20,000 common shares of Axsome Therapeutics on 08/26/2025 through Charles Schwab, with an aggregate market value of $2,400,658.

Who acquired the shares and when were they acquired?

The shares were acquired by exercise and hold from Axsome Therapeutics, Inc. on 05/27/2016 (1,298 shares) and 03/15/2017 (18,702 shares), paid in cash.

Were there recent sales by the same person before this filing?

Yes. The filing discloses a sale on 08/22/2025 of 16,694 shares for $2,004,598 by the seller identified as Roger Jeffs.

How large is the proposed sale relative to outstanding shares?

The proposed 20,000-share sale is about 0.04% of the reported 49,901,487 shares outstanding, based on figures in the filing.

Does the filing state whether a Rule 10b5-1 plan was used?

No plan adoption date or Rule 10b5-1 instruction date is provided in the filing.